Trial Profile

Long-term Effectiveness and Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Girls Aged 9-17 Years

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
Indications Human papillomavirus infections
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

12 Feb 2024 New trial record
10 Feb 2024 Planned initiation date changed from 15 Feb 2024 to 20 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com